Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Material Agreement (Nov 12, 2025)

Reports
Material Agreements·Financial Events·Securities & Listing+1
Filing Date
Filed November 12, 2025
Period End
November 6, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed November 12, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. completed its previously announced sale of $1,500.0 milliona aggregate principal amount of convertible senior notes on November 12, 2025.

The offering consisted of $750.0 millionb of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, each including $100.0 million of additional notes purchased through the initial purchasers' option. The company received net proceeds of approximately $1.47 billion, of which about $182.7 million was used to fund capped call transactions, and it paid approximately $1.020 billion in cash, including accrued interest, to repurchase portions of its outstanding 0.25% Convertible Senior Notes due 2027 and 1.00% Convertible Senior Notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and potential future note repurchases.

The notes are unsecured and rank effectively junior to secured indebtedness and structurally subordinated to liabilities of subsidiaries. The initial conversion rate is 11.4683 shares per $1,000c principal amount, equivalent to a conversion price of approximately $87.20 per share. The company may settle conversions in cash, shares, or a combination at its election.

The 2031 notes carry no regular interest, while the 2032 notes pay 0.875% semi-annually beginning May 15, 2026. The company may not redeem the 2031 notes before February 20, 2029, or the 2032 notes before November 20, 2029. The capped call transactions have an initial cap price of $136.78d per share, which the filing states represents a 100% premium over the November 5, 2025 closing price for both series.

Investors should note the holder protections in the indentures, including repurchase rights upon a fundamental change and cross-default provisions tied to indebtedness of at least $50.0 million. The notes were sold under Rule 144A to qualified institutional buyers and have not been registered under the Securities Act.

Key Highlights

  1. Issued $1,500.0 million in convertible senior notes: $750.0 million of 0% notes due 2031 and $750.0 million of 0.875% notes due 2032, each including a $100.0 million option exercise
  2. Received net proceeds of approximately $1.47 billion after initial purchasers' discounts, commissions, and estimated offering expenses
  3. Used about $182.7 million for capped call transactions with an initial cap price of $136.78 per share
  4. Paid approximately $1.020 billion in cash, including accrued interest, to repurchase portions of the 0.25% notes due 2027 and 1.00% notes due 2028
  5. Initial conversion price of approximately $87.20 per share (11.4683 shares per $1,000 principal amount)
  6. Company may not redeem the 2031 notes before February 20, 2029, or the 2032 notes before November 20, 2029
  7. Notes are unsecured, effectively junior to secured debt, and structurally subordinated to subsidiary liabilities

Frequently Asked Questions

  1. How much capital did Halozyme raise and how will it be used?

    The company raised $1,500.0 million in aggregate principal through the notes, with net proceeds of approximately $1.47 billion. About $182.7 million funded the capped call transactions and approximately $1.020 billion in cash was paid to repurchase portions of its 2027 and 2028 convertible notes, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases or repayment at maturity.

  2. What are the key terms of the new convertible notes?

    The 2031 notes are 0% convertible senior notes that pay no regular interest and do not accrete. The 2032 notes are 0.875% convertible senior notes paying interest semi-annually on May 15 and November 15, beginning May 15, 2026. Both are convertible into cash and, if applicable, common stock at the company's election, at an initial conversion rate of 11.4683 shares per $1,000 principal amount, or about $87.20 per share.

  3. What is the purpose of the capped call transactions?

    The filing states the capped call transactions are expected generally to reduce potential dilution to common stockholders upon conversion of the notes, or offset cash payments the company must make above the principal amount of converted notes, subject to a cap. The initial cap price is $136.78 per share, which the filing states is a 100% premium above the November 5, 2025 Nasdaq closing price for both series. The capped call transactions are separate from the notes and do not affect noteholder rights.

  4. When can holders convert their notes and when can the company redeem them?

    Holders may convert during any calendar quarter after the quarter ending March 31, 2026, if the stock price exceeds 130% of the conversion price for at least 20 of the 30 consecutive trading days ending on the last trading day of the prior quarter. Other conversion triggers include trading price conditions, certain corporate events, and a company redemption call. Free conversion is permitted from August 15, 2030 for the 2031 notes and May 15, 2032 for the 2032 notes until the second scheduled trading day before maturity. The company may not redeem the 2031 notes before February 20, 2029, or the 2032 notes before November 20, 2029.

  5. What protections do noteholders have?

    Upon a fundamental change, holders may require repurchase for cash at 100% of principal plus accrued interest, and the company may increase the conversion rate for holders converting in connection with a make-whole fundamental change. Events of default include payment defaults, failure to convert or deliver required notices, and cross-defaults on indebtedness of at least $50.0 million. The notes were sold in a Rule 144A offering to qualified institutional buyers and have not been registered under the Securities Act.